title: Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
abstract: The deposition of misfolded peptides and proteins in the form of amyloid fibrils is the hallmark of nearly fifty medical disorders, including Alzheimer's disease, Parkinson's disease, prion diseases and type II diabetes. These disorders, referred to as amyloidoses, generally become apparent late in life. Their psycho-sociological and economic incidence in western societies will be therefore considerable in the coming decades due to the ageing of the population. Neither preventing nor curative treatments are available yet. These disorders constitute therefore a medical challenge of great importance. Thus, an extensive research is being carried out to understand, at the molecular level, (i) how amyloidogenic proteins misfold and convert from their soluble form into amyloid fibrils, and (ii) how these aggregates or some of their oligomeric precursor species are toxic. The formation of amyloid fibrils proceeds through a complex nucleation/polymerisation mechanism with the formation of various species, including small oligomers. In this review, we focus on how VHHs or nanobodies, the antigen-binding domains of camelid heavy-chain antibodies, are being increasingly used to characterise each of the species formed on the pathway of fibril formation in terms of structure, stability, kinetics of formation and toxicity. We first introduce the characteristic features of nanobodies compared to those of conventional antibody fragments. Thereafter, we discuss how nanobodies, due to their unique properties, are used as probes to dissect the molecular mechanisms of misfolding and aggregation of six proteins associated with diseases, i.e. human lysozyme, β2-microglobulin, α-synuclein, prion, polyadenylate binding protein nuclear 1 and amyloid β-peptide. A brief general presentation of each disease and the associated peptide/protein is also provided. In addition, we discuss how nanobodies could be used as early diagnostic tools and as novel strategies to treat diseases associated with protein misfolding and aggregation.
authors: Laboratory of Enzymology and Protein Folding, Centre for Protein Engineering, University of Liège, Liège, Belgium.
authors: Coralie
authors: C
authors: Pain
authors: Laboratory of Enzymology and Protein Folding, Centre for Protein Engineering, University of Liège, Liège, Belgium.
authors: Janice
authors: J
authors: Dumont
authors: Laboratory of Enzymology and Protein Folding, Centre for Protein Engineering, University of Liège, Liège, Belgium. Electronic address: mdumoulin@ulg.ac.be.
authors: Mireille
authors: M
authors: Dumoulin
mesh_terms: D000818:Animals; D002161:Camelids, New World / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D066263:Protein Aggregation, Pathological / Q000188:drug therapy* / Q000276:immunology; D057165:Proteostasis Deficiencies / Q000188:drug therapy* / Q000276:immunology; D061905:Single-Domain Antibodies / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D007143:Immunoglobulin Heavy Chains; D061905:Single-Domain Antibodies
keywords: Amyloidoses; Inhibition of protein misfolding and aggregation; Nanobody; Protein misfolding diseases; V(H)H; Variable domain of heavy-chain antibody